Figure 4
Figure 4. Kaplan-Meier survival functions for overall survival according to the presence of complex karyotypes, genetic lesions in TP53, or POT1 gene mutations. OS (A) in 30 patients with vs 124 patients without complex karyotypes, (B) in 17 vs 137 patients with deletions or mutations in TP53, (C) or with either one or both of these 2 genetic features present (109 patients with no complex karyotypes and no TP53 hit vs 22 patients with complex karyotypes and no TP53 lesion, vs 8 patients with a TP53 mutation or deletion and no complex karyotype, vs 8 patients with complex karyotypes and a TP53 mutation or deletion). (D) OS in 13 patients with vs 148 patients without POT1 mutations and treated with Clb-G or Clb-R, because all except 1 of 13 patients with POT1 mutations had been assigned to a chemoimmunotherapy study arm. Complex indicates complex karyotypes; noncomplex, absence of complex karyotypes; TP53 def, presence of a deletion or mutation in TP53).

Kaplan-Meier survival functions for overall survival according to the presence of complex karyotypes, genetic lesions in TP53, or POT1 gene mutations. OS (A) in 30 patients with vs 124 patients without complex karyotypes, (B) in 17 vs 137 patients with deletions or mutations in TP53, (C) or with either one or both of these 2 genetic features present (109 patients with no complex karyotypes and no TP53 hit vs 22 patients with complex karyotypes and no TP53 lesion, vs 8 patients with a TP53 mutation or deletion and no complex karyotype, vs 8 patients with complex karyotypes and a TP53 mutation or deletion). (D) OS in 13 patients with vs 148 patients without POT1 mutations and treated with Clb-G or Clb-R, because all except 1 of 13 patients with POT1 mutations had been assigned to a chemoimmunotherapy study arm. Complex indicates complex karyotypes; noncomplex, absence of complex karyotypes; TP53 def, presence of a deletion or mutation in TP53).

Close Modal

or Create an Account

Close Modal
Close Modal